Charting a path toward combination therapy for Alzheimer's disease

Expert Review of Neurotherapeutics

Volumn 15, Issue 1, 2014, Pages 107-113

  Stephenson, Diane ^a   Perry, Dan ^b   Bens, Cynthia ^b   Bain, Lisa J ^c   Berry, Donald ^d   Krams, Michael ^e   Sperling, Reisa ^f   Dilts, David ^g   Luthman, Johan ^h   Hanna, Debra ^c   McKew, John ⁱ   Temple, Robert ^j   Fields, F Owen ^k   Salloway, Stephen ^l   Katz, Russell ^c  

^a CAMD Critical Path Institute   (United States)

^b Alliance for Aging Research   (United States)

^c Berry Consultants LLC ^*  (United States)

^d BERRY CONSULTANTS   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h EISAI INC   (United States)

ⁱ National Center for Advancing Translational Science   (United States)

^j CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^k PFIZER INC   (United States)

^l BUTLER HOSPITAL   (United States)

more..

Author keywords

Alzheimer's disease; Co development; co development; collaboration; combination therapy; novel therapy

Indexed keywords

BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; MEMANTINE; NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; CLINICAL PATHWAY; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG EFFECT; DRUG REPOSITIONING; HUMAN; MONOTHERAPY; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; REMISSION; REVIEW; TUBERCULOSIS; ANIMAL; DRUG CONTROL; DRUG SCREENING; ORGANIZATION; PROCEDURES; PUBLIC-PRIVATE PARTNERSHIP; TRENDS;

ACADEMIES AND INSTITUTES; ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG AND NARCOTIC CONTROL; DRUG EVALUATION; HUMANS; PUBLIC-PRIVATE SECTOR PARTNERSHIPS;

EID: 84920834831     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.995168     Document Type: Review

References (30)

1. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004; 430(7000):631-9
2. Jack CR Jr, Albert M, Knopman DS, et al. Introduction to revised criteria for the diagnosis of Alzheimer's disease: national Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 2011;7(3):257-62
3. DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res 2008;68(21): 8643-53
4. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 2001;61 Suppl 2:14-21
5. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21(6):976-83
6. Berry DA. Adaptive clinical trials: the promise and the caution. J Clin Oncol 2010;29(6):606-9
7. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86(1):97-100
8. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010; 9(7):702-16
9. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012;366(10):893-903
10. Peters O, Lorenz D, Fesche A, et al. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J Nutr Health Aging 2012;16(6):544-8
11. Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Alzheimers Dement 2013;9(3):326-31
12. Herrup K, Carrillo M, Schenk D, et al. Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease. Alzheimers Dement 2013;9(4):452-8
13. Bohrmann B, Caruso A, Tanghe A, et al. Combination therapy with Gantenerumab and BACE inhibitor accelerates amyloid lowering: New paradigm for treatment of Alzheimer's disease The 11th International Conference on Alzheimer's & Parkinson's Diseases; Florence, Italy; 2013
14. Food and Drug Administration. Guidance for industry: Codevelopment of two or more unmarketed investigational drugs for use in combination. 2010. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM236669.pdf [Last accessed on 13/04/14]
15. Woodcock J, Griffin JP, Behrman RE. Development of novel combination therapies. N Engl J Med 2011;364(11): 985-7
16. Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011;3(111):111cm33
17. Teipel SJ, Sabri O, Grothe M, et al. Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease. J Alzheimers Dis 2013;33(Suppl 1): S329-47
18. Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9(7):560-74
19. Morris JC, Selkoe DJ, Holtzman DM, et al. Emerging consensus for Alzheimer's biomarkers in clinical trials. Neurobiol Aging 2011;32:S1-S66
20. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9(1):119-28
21. Jack CR Jr, Vemuri P, Wiste HJ, et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 2011;68(12): 1526-35
22. Jack CR Jr, Vemuri P, Wiste HJ, et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol 2012;69(7):856-67
23. Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133(11):3336-48
24. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical, cognitive, and biomarker changes in the Dominantly Inherited Alzheimer Network. N Engl J Med 2012; 367(9):795-804
25. Snyder HM, Bain LJ, Egge R, Carrillo MC. Alzheimer's disease public-private partnerships: a landscape of the global nonprofit community. Alzheimers Dement 2013;9(4):466-71
26. World Health Organization. Global Tuberculosis Report; Geneva, Switzerland; 2012
27. Romero K, de Mars M, Frank D, et al. The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases. Clin Pharmacol Ther 2009;86(4):365-7
28. Stephenson D, Aviles E, Bain LJ, et al. Coalition Against Major Diseases: precompetitive collaboration and regulatory paths to accelerating drug development for neurodegenerative diseases. Therapeutic Innovation & Regulatory Science 2013; 47(6):632-8
29. Neville J, Kopko S, Broadbent S et al., for the Coalition Against Major Diseases, Development of a unified clinical trial database for Alzheimer's disease, Alzheimer's and Dementia, in press
30. Worley S. After disappointments, Alzheimer's researchers seek out new paths: biomarkers and combination therapies may lead to disease-modifying treatments, experts say. P T 2014;39(5):365-74